|
MOTILITY AND INVASION
|
5P01CA100324-12
|
|
$0
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
MOTILITY AND INVASION
|
6P01CA100324-13
|
$2,028,990
|
$202,899
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Cellular biofactories for therapeutic protein synthesis in tumor microenvironment
|
1R21CA193064-01
|
$1
|
$1
|
BHATNAGAR, PARIJAT
|
BAYLOR COLLEGE OF MEDICINE
|
|
Enhancing T Cell Therapy of Cancer
|
5P01CA094237-13
|
$1,932,287
|
$966,144
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
5P50CA126752-09
|
$2,184,999
|
$524,400
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-02
|
$2,184,998
|
$131,100
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
1R01CA183984-01A1
|
$472,669
|
$236,335
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
DF/HCC Kidney Cancer SPORE
|
2P50CA101942-11A1
|
$2,185,000
|
$262,200
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting orphan nuclear receptor TR3/Nur77 for tumor angiogenesis
|
1R03CA191463-01A1
|
$87,000
|
$43,500
|
ZENG, HUIYAN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Image-guided EMT inhibition for treating metastatic breast cancer
|
1R01CA194518-01A1
|
$473,853
|
$156,371
|
LU, ZHENG-RONG
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Next-generation mouse gene-targeting technology to model tumorigenesis
|
5R21CA181859-03
|
$206,843
|
$206,843
|
WANG, ZHENGHE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A novel soluble receptor-based therapy for Kidney Cancer
|
5R21CA178157-02
|
$172,369
|
$86,185
|
WELFORD, SCOTT
|
CASE WESTERN RESERVE UNIVERSITY
|
|
HAT Inhibition to Impair Foxp3+ Treg Function and Boost Anti-Tumor Immunity
|
5R01CA158941-05
|
$343,724
|
$103,117
|
HANCOCK, WAYNE
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
MicroRNA in Acute Myeloid Leukemia
|
5R01CA159845-05
|
$317,475
|
$317,475
|
GRIMES, H.
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
5R01CA157537-05
|
$317,475
|
$317,475
|
PANG, QISHEN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
CpG-siRNA Conjugates to Target Acute Myeloid Leukemia
|
5R01CA155367-05
|
$348,600
|
$348,600
|
KORTYLEWSKI, MARCIN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural
|
1R01CA198076-01
|
$621,329
|
$310,665
|
PORTNOW, JANA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient
|
5U01CA183012-02
|
$496,292
|
$248,146
|
ZAIA, JOHN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Elucidating the role of microRNAs in the initiation of multiple myeloma
|
4R00CA172292-03
|
$248,999
|
$74,700
|
ZHAO, JIANJUN
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Optimization of a clinical stage nanoparticle drug delivery platform
|
1R43CA186410-01A1
|
$184,129
|
$92,065
|
BROWN, BOB
|
DICERNA PHARMACEUTICALS, INC.
|
|
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
|
5P01CA154291-04
|
$3,698,322
|
$776,648
|
BIGNER, DARELL
|
DUKE UNIVERSITY
|
|
Targeting Translation Control in Malignant Glioma
|
5R01CA124756-09
|
$253,655
|
$253,655
|
GROMEIER, MATTHIAS
|
DUKE UNIVERSITY
|
|
Duke SPORE in Brain Cancer
|
5P50CA190991-02
|
$2,185,000
|
$87,400
|
SAMPSON, JOHN
|
DUKE UNIVERSITY
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
5R01CA123490-08
|
$251,191
|
$62,798
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Pediatric Oncology Research Training Program
|
5T32CA009351-37
|
$259,426
|
$51,885
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Pacific Ovarian Cancer Research Consortium
|
3P50CA083636-15S1
|
$901,655
|
$54,099
|
DRESCHER, CHARLES
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Role of the Perivascular Microenvironment in Primary and Metastatic Brain Tumors
|
5U54CA163167-05
|
$841,065
|
$92,517
|
HOLLAND, ERIC
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted therapy of B cell malignances with CAR-T cells of defined composition
|
5R01CA136551-07
|
$560,424
|
$280,212
|
RIDDELL, STANLEY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Hematopoietic Chimerism after Stem Cell Allografts
|
5P01CA078902-17
|
$2,019,079
|
$948,967
|
STORB, RAINER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Mechanistic significance of a novel molecular target in the FOXO signaling pathwa
|
5R03CA186944-02
|
$77,750
|
$38,875
|
KASID, USHA
|
GEORGETOWN UNIVERSITY
|
|
Investigation of a candidate chemotherapy-induced nausea sensory circuit
|
5F30CA177170-02
|
$48,120
|
$24,060
|
WILLIAMS, ERIKA
|
HARVARD MEDICAL SCHOOL
|
|
Gene Therapy and Radiation Therapy for Prostate Cancer
|
5R01CA160289-04
|
$303,988
|
$151,994
|
FREYTAG, SVEND
|
HENRY FORD HEALTH SYSTEM
|
|
Tissue-specific tumor suppressor effects of p53
|
1R01CA200256-01
|
$400,089
|
$200,045
|
MANFREDI, JAMES
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Genetic Therapy for Fanconi Anemia
|
5R01CA155294-05
|
$319,550
|
$319,550
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Platform for MR-Guided Neurotherapeutic Drug Delivery
|
2R44CA177205-02
|
$938,975
|
$469,488
|
BARKER, EDWARD
|
INSERT, INC.
|
|
Nanoparticles for selective and combinatorial delivery of siRNA to brain cancer
|
1F31CA196163-01A1
|
$43,120
|
$43,120
|
KOZIELSKI, KRISTEN
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Prostate Cancer
|
5P50CA058236-20
|
$1,793,395
|
$358,679
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
BMP4 Engineered Mesenchymal Stem Cell Therapy for Glioblastoma
|
1R01CA183827-01A1
|
$329,461
|
$329,461
|
QUINONES-HINOJOSA, ALFREDO
|
JOHNS HOPKINS UNIVERSITY
|
|
Developing Nanotechnology to Target HMGA1 in Pancreatic Cancer
|
5R03CA182679-02
|
$81,000
|
$40,500
|
RESAR, LINDA
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Cervical Cancer
|
5P50CA098252-12
|
$2,174,869
|
$282,733
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Enhancing HPV-16 E6/E7 Specific Antitumor Immunity
|
5R01CA114425-09
|
$303,371
|
$151,686
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Ovarian cancer gene therapy using HPV pseudovirion
|
5R01CA183040-02
|
$336,150
|
$336,150
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Histone Methyltransferases as a Target for Lung Cancer Prevention
|
5R01CA183296-02
|
$581,472
|
$290,736
|
BELINSKY, STEVEN
|
LOVELACE BIOMEDICAL & ENVIRONMENTAL RES
|
|
TCR Gene Modified T Cells for Adoptive Immunotherapy
|
5P01CA154778-05
|
$3,406,082
|
$1,873,345
|
NISHIMURA, MICHAEL
|
LOYOLA UNIVERSITY CHICAGO
|
|
TCR Gene Transfer for Treating HCV-Associated Malignancies
|
5F30CA180731-02
|
$29,942
|
$29,942
|
SPEAR, TIMOTHY
|
LOYOLA UNIVERSITY CHICAGO
|
|
Identifying vulnerabilities and therapeutic targets in Glioma Stem Cells
|
1K22CA197053-01
|
$200,880
|
$200,880
|
BADR, CHRISTIAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
MicroRNA Therapy for Lymph Node Metastatic Breast Cancer
|
5R01CA163461-04
|
$395,711
|
$395,711
|
MEDAROVA, ZDRAVKA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Center for Molecular Imaging Research at MGH/HMS
|
5P50CA086355-16
|
$1,377,346
|
$55,094
|
WEISSLEDER, RALPH
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Peptide-mediated delivery of siRNA for treatment of ovarian cancer
|
5F32CA177094-02
|
$57,962
|
$57,962
|
KWON, ESTER
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Polymeric Nanoparticles for siRNA Delivery to Bone Marrow Endothelium to Disrupt
|
1F32CA200351-01
|
$50,690
|
$50,690
|
MITCHELL, MICHAEL
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
Total relevant funding to Gene Therapy for this search: $39,508,420
|